Radiotherapeutics

Medical radiotherapeutics are a rapidly advancing area of oncology that uses targeted radionuclides to deliver cytotoxic radiation directly to malignant tissue. Alpha emitters, such as actinium-225, emit high-energy, short-range particles, enabling potent tumour cell destruction with minimal impact on surrounding structures. These agents are being developed for prostate, neuroendocrine and brain cancers through receptor- or antibody-based targeting strategies. Beta-emitting radionuclides, including yttrium-90 and lutetium-177, remain central to the treatment of hepatocellular carcinoma, lymphoma, and metastatic prostate disease. Radium-223 has demonstrated value in managing bone metastases, particularly in advanced prostate cancer. By combining molecular specificity with controlled radiation delivery, radiotherapeutics are reshaping cancer care through increasingly precise and personalised treatment approaches.

home » radiotherapeutics